Roivant Sciences Ltd. (ROIV)
NASDAQ
Closed
Sep 10, 2026
Day's Range
40.2252 wk Range
13.39Profile - ROIV - Roivant Sciences Ltd.
Profile
Mic Code
XNGS
Sector
Healthcare
Industry
Biotechnology
Employees
750
Roivant Sciences Ltd. is an American multinational healthcare company that develops transformative medicines and technologies by creating agile, focused subsidiaries called Vants. These Vants target specific therapeutic areas, including autoimmune diseases through Immunovant, severe autoimmune conditions via Priovant, and pulmonary diseases with Pulmovant. The company applies technology across drug discovery, development, and commercialization to accelerate the delivery of innovative therapies to patients. Roivant Sciences Ltd. maintains a broad pipeline of investigational drugs across multiple areas such as immunology, dermatology, rare diseases, and inflammatory conditions. Notable Vants include Kinevant for rare autoimmune and inflammatory diseases, and health technology units like Datavant for healthcare data sharing and Lokavant for clinical trial optimization. Founded in 2014 and headquartered in New York City with offices in Boston and Basel, Roivant Sciences Ltd. operates as a parent to these specialized entities, aligning incentives for efficient execution in the biopharmaceutical sector.
Profile Details
Type
Common Stock
Ceo
Mr. Matthew Gline
Address
11-12 St. James's Square
City
London
Zip
SW1Y 4LB
Country
United Kingdom
Phone
44 20 7400 3347
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
